review Open AccessTop 1% cited

Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis

JNCI Journal of the National Cancer Institute · 2005 · Vol. 97(3) · pp. 188–194

Davide Mauri✉(Tufts University)N. Pavlidis(Tufts Medical Center)John P. A. Ioannidis(University of Ioannina)

Abstract

Neoadjuvant therapy was apparently equivalent to adjuvant therapy in terms of survival and overall disease progression. Neoadjuvant therapy, compared with adjuvant therapy, was associated with a statistically significant increased risk of loco-regional recurrence when radiotherapy without surgery was adopted.

Breast Cancer Treatment Studies Breast Lesions and Carcinomas Breast Implant and ReconstructionMedicineBreast cancerNeoadjuvant therapyRadiation therapyAdjuvant therapyRelative riskRegimenInternal medicineRandomized controlled trialSystemic therapy

MeSH terms

Antineoplastic AgentsBreast NeoplasmsFemaleHumansOdds RatioSurvival AnalysisRandomized Controlled Trials as TopicTreatment OutcomeChemotherapy, AdjuvantDisease ProgressionNeoadjuvant Therapy

Citations

1,205

FWCI

13.17

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Efficacy of single cycle neoadjuvant chemotherapy in carcinoma breast